Hydroxychloroquine: a multifaceted treatment in lupus

scientific article published on 19 May 2014

Hydroxychloroquine: a multifaceted treatment in lupus is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.LPM.2014.03.007
P698PubMed publication ID24855048

P50authorNathalie Costedoat-ChalumeauQ47262464
P2093author name stringNathalie Morel
Véronique Le Guern
Bertrand Dunogué
Gaëlle Guettrot-Imbert
P433issue6 Pt 2
P921main subjecthydroxychloroquineQ421094
P304page(s)e167-80
P577publication date2014-05-19
P1433published inPresse médicaleQ127260618
P1476titleHydroxychloroquine: a multifaceted treatment in lupus
P478volume43

Reverse relations

cites work (P2860)
Q40795030Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification
Q28069143Anti-inflammatory and Immunomodulatory Effects of Antibiotics and Their Use in Dermatology
Q33650548Association between use of disease-modifying antirheumatic drugs and diabetes in patients with ankylosing spondylitis, rheumatoid arthritis, or psoriasis/psoriatic arthritis: a nationwide, population-based cohort study of 84,989 patients
Q26999216Autophagy in cancer
Q100153806C-ter TLR7 dimer binds HCQ
Q100153807C-ter TLR9 dimer binds HCQ
Q38897521CHAI and LATAIE: new genetic diseases of CTLA-4 checkpoint insufficiency
Q99413596COVID-19 in systemic lupus erythematosus: data from a survey on 417 patients
Q38360827Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases
Q55208303Chloroquine and hydroxychloroquine are associated with reduced cardiovascular risk: a systematic review and meta-analysis.
Q94685368Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data
Q47441501Compliance and persistence with hydroxychloroquine in South Korean patients with systemic lupus erythematosus.
Q97644054Coronavirus Disease 2019 (COVID-19) and Transplantation: Pharmacotherapeutic Management of Immunosuppression Regimen
Q54218397Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review.
Q33422958Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus
Q38776952Development and validation of a clinical HPLC method for the quantification of hydroxychloroquine and its metabolites in whole blood
Q40556363Disease Activity During Pregnancy and the First Year Postpartum in Women With Systemic Lupus Erythematosus
Q38806513Dysregulation of innate and adaptive serum mediators precedes systemic lupus erythematosus classification and improves prognostic accuracy of autoantibodies
Q48120219Early cutaneous eruptions after oral hydroxychloroquine in a lupus erythematosus patient: A case report and review of the published work
Q64118839Effect of Hydroxychloroquine and Anti-BDCA2 mAb Treatment on pDC IFNα Production From Patients Affected With Cutaneous Lupus Erythematosus
Q90415013Flares in systemic lupus erythematosus: diagnosis, risk factors and preventive strategies
Q38560780Genomics of Immune Diseases and New Therapies
Q47842487Health status and concomitant prescription of immunosuppressants are risk factors for hydroxychloroquine non-adherence in systemic lupus patients with prolonged inactive disease.
Q97075375Hippocampal Atrophy in Systemic Lupus Erythematosus Patients without Major Neuropsychiatric Manifestations
Q93213302Hydroxychloroquine and "off-label" utilization in the treatment of oral conditions
Q95633060Hydroxychloroquine effects on psoriasis: a systematic review and a cautionary note for COVID-19 treatment
Q41915768Hydroxychloroquine hindering of diabetic isletopathy carries its signature on the inflammatory cytokines.
Q39031764Hydroxychloroquine in systemic lupus erythematosus (SLE).
Q99726452Hydroxychloroquine levels in patients with systemic lupus erythematosus: whole blood is preferable but serum levels also detect non-adherence
Q39172826Hydroxychloroquine retinopathy
Q47396929Hydroxycloroquine blood concentration in lupus nephritis: a determinant of disease outcome?
Q38883883Immunomodulators in SLE: Clinical evidence and immunologic actions
Q58604686Intrauterine fetal deaths related to antiphospholipid syndrome: a descriptive study of 65 women
Q97533087Is hydroxychloroquine beneficial for COVID-19 patients?
Q52626305Isolated acute lupus pneumonitis as the initial presentation of systemic lupus erythematosus in an 8-year-old girl.
Q40725518Low-dose aspirin as primary prophylaxis for cardiovascular events in systemic lupus erythematosus: a long-term retrospective cohort study
Q64084551Lysosomal pH Is Regulated in a Sex Dependent Manner in Immune Cells Expressing
Q38998709NETopathies? Unraveling the Dark Side of Old Diseases through Neutrophils
Q59808159Predictors of persistent disease activity and long quiescence in systemic lupus erythematosus: results from the Hopkins Lupus Cohort
Q96686028Prevalence of hydroxychloroquine retinopathy using 2018 Royal College of Ophthalmologists diagnostic criteria
Q42043474Pro-inflammatory Ca++-activated K+ channels are inhibited by hydroxychloroquine
Q38773552Refractory pulmonary sarcoidosis - proposal of a definition and recommendations for the diagnostic and therapeutic approach
Q35877606Reproductive outcomes following hydroxychloroquine use for autoimmune diseases: a systematic review and meta-analysis
Q38431886Stem cell therapies for systemic lupus erythematosus: current progress and established evidence
Q89784271Systemic lupus erythematosus aggravates atherosclerosis by promoting IgG deposition and inflammatory cell imbalance
Q35530248Systemic lupus erythematosus and thrombosis
Q58698067Up-Regulation of TLR7-Mediated IFN-α Production by Plasmacytoid Dendritic Cells in Patients With Systemic Lupus Erythematosus
Q89338390[Lupus nephritis]
Q89894663[Tapering and termination of immunosuppressive therapy : Systemic lupus erythematosus]

Search more.